Nowa Zelandia - angielski - Medsafe (Medicines Safety Authority)

pfizer new zealand limited - axitinib 5mg;   - film coated tablet - 5 mg - active: axitinib 5mg   excipient: croscarmellose sodium lactose monohydrate magnesium stearate microcrystalline cellulose opadry red 32k15441 - treatment of patients with advanced renal cell carcinoma after failure of one prior systemic therapy.

Nowa Zelandia - angielski - Medsafe (Medicines Safety Authority)

astrazeneca limited - primaquine phosphate 7.5mg - tablet - 7.5 mg - active: primaquine phosphate 7.5mg

Nowa Zelandia - angielski - Medsafe (Medicines Safety Authority)

sanofi-aventis new zealand limited - rifampicin 450mg - tablet - 450 mg - active: rifampicin 450mg

Nowa Zelandia - angielski - Medsafe (Medicines Safety Authority)

sanofi-aventis new zealand limited - rifampicin 600mg - tablet - 600 mg - active: rifampicin 600mg excipient: acacia calcium stearate carmellose sodium carnauba wax colloidal silicon dioxide colophony erythrosine ethanol gelatin hard paraffin kaolin lactose monohydrate magnesium carbonate magnesium stearate maize starch microcrystalline cellulose povidone purified talc purified water sodium laurilsulfate sucrose titanium dioxide white beeswax - tuberculosis rifampicin is indicated in the treatment of all forms of tuberculosis, including fresh, advanced, chronic and drug resistant cases. rifampicin should be used in conjunction with at least one other antituberculosis medicine. leprosy rifampicin is indicated in the treatment of multibacillary and paucibacillary leprosy to effect a conversion of the infectious state to a non-infectious state. rifampicin should be used in conjunction with at least one other anti-leprosy drug. methicillin-resistant staphylococcal infections (mrsa) rifampicin can be used as an alternative to vancomycin in the treatment of mrsa. in such circumstances an appropriate companion antibiotic (e.g. fusidic acid) should always be employed. serious staphylococcal infections rifampicin has been used for the treatment of both life-threatening and serious staphylococcal infections. in such circumstances an appropriate companion antibiotic should be employed. brucellosis rifampicin may be used for the treatment of brucellosis. in such circumstances doxycycline should also be used. meningococcal carriers rifampicin is indicated for the treatment of asymptomatic carriers of n. meningitidis to eliminate meningococci from the nasopharynx. (rifampicin is not indicated for the treatment of meningococcal infection because of the possibility of the rapid emergence of resistant organisms). haemophilus influenzae rifampicin is indicated for the treatment of asymptomatic carriers of h influenzae and as chemoprophylaxis of exposed children of 4 years of age or younger. other infections infections caused by rifampicin-sensitive microorganisms such as staphylococci, streptococci, n gonorrhoeae, proteus sp., h. influenzae, e. coli and legionella sp. to prevent emergence of resistant organisms, rifampicin should be given with another antibacterial agent to which the organism has been shown to be susceptible.

Nowa Zelandia - angielski - Medsafe (Medicines Safety Authority)

sanofi-aventis new zealand limited - disopyramide 150mg (as base) - capsule - 150 mg - active: disopyramide 150mg (as base) excipient: gelatin magnesium stearate maize starch purified talc starch titanium dioxide

Nowa Zelandia - angielski - Medsafe (Medicines Safety Authority)

sandoz new zealand limited - tacrolimus monohydrate 0.511mg equivalent to 0.5 mg tacrolimus - capsule - 0.5 mg - active: tacrolimus monohydrate 0.511mg equivalent to 0.5 mg tacrolimus excipient: capsugel ivory g4ics000511 croscarmellose sodium hypromellose lactose monohydrate magnesium stearate - primary immunosuppression in liver, kidney, pancreas, kidney-pancreas, lung or heart allograft recipients and rescue use in liver, kidney or other solid organ (heart, lung, pancreas or kidneys) transplantation, that has either failed conventional immunosuppressive agents, or where such agents are producing intolerable side effects.

Nowa Zelandia - angielski - Medsafe (Medicines Safety Authority)

sandoz new zealand limited - tacrolimus monohydrate 1.022mg equivalent to 1 mg tacrolimus - capsule - 1 mg - active: tacrolimus monohydrate 1.022mg equivalent to 1 mg tacrolimus excipient: croscarmellose sodium hypromellose capsugel white/brown g4ics000510 lactose monohydrate magnesium stearate - primary immunosuppression in liver, kidney, pancreas, kidney-pancreas, lung or heart allograft recipients and rescue use in liver, kidney or other solid organ (heart, lung, pancreas or kidneys) transplantation, that has either failed conventional immunosuppressive agents, or where such agents are producing intolerable side effects.

Nowa Zelandia - angielski - Medsafe (Medicines Safety Authority)

sandoz new zealand limited - tacrolimus monohydrate 5.11mg equivalent to 5 mg tacrolimus - capsule - 5 mg - active: tacrolimus monohydrate 5.11mg equivalent to 5 mg tacrolimus excipient: croscarmellose sodium hypromellose lactose monohydrate magnesium stearate opaque orange g3ics000767 - primary immunosuppression in liver, kidney, pancreas, kidney-pancreas, lung or heart allograft recipients and rescue use in liver, kidney or other solid organ (heart, lung, pancreas or kidneys) transplantation, that has either failed conventional immunosuppressive agents, or where such agents are producing intolerable side effects.

Nowa Zelandia - angielski - Medsafe (Medicines Safety Authority)

merck sharp & dohme (new zealand) limited - ezetimibe 10mg; simvastatin 10mg - tablet - 10/10mg - active: ezetimibe 10mg simvastatin 10mg excipient: butylated hydroxyanisole citric acid monohydrate croscarmellose sodium hypromellose lactose monohydrate magnesium stearate microcrystalline cellulose propyl gallate - homozygous familial hypercholesterolaemia vytorin is indicated for the reduction of elevated total-c and ldl-c levels in adult and adolescent (10 to 17 years of age) patients with hofh. patients may also receive adjunctive treatments (e.g., ldl apheresis).

Nowa Zelandia - angielski - Medsafe (Medicines Safety Authority)

merck sharp & dohme (new zealand) limited - ezetimibe 10mg; simvastatin 20mg - tablet - 10/20mg - active: ezetimibe 10mg simvastatin 20mg excipient: butylated hydroxyanisole citric acid monohydrate croscarmellose sodium hypromellose lactose monohydrate magnesium stearate microcrystalline cellulose propyl gallate - homozygous familial hypercholesterolaemia vytorin is indicated for the reduction of elevated total-c and ldl-c levels in adult and adolescent (10 to 17 years of age) patients with hofh. patients may also receive adjunctive treatments (e.g., ldl apheresis).